4.12
price down icon1.20%   -0.05
after-market アフターアワーズ: 4.16 0.04 +0.97%
loading
前日終値:
$4.17
開ける:
$4.24
24時間の取引高:
4.77M
Relative Volume:
2.07
時価総額:
$362.04M
収益:
$30.91M
当期純損益:
$-209.47M
株価収益率:
-1.238
EPS:
-3.3279
ネットキャッシュフロー:
$-147.13M
1週間 パフォーマンス:
+4.57%
1か月 パフォーマンス:
-3.29%
6か月 パフォーマンス:
-46.84%
1年 パフォーマンス:
-20.62%
1日の値動き範囲:
Value
$4.11
$4.425
1週間の範囲:
Value
$3.85
$4.425
52週間の値動き範囲:
Value
$3.55
$11.24

Verastem Inc Stock (VSTM) Company Profile

Name
名前
Verastem Inc
Name
セクター
Healthcare (1104)
Name
電話
(781) 292-4200
Name
住所
117 KENDRICK STREET, NEEDHAM, MA
Name
職員
102
Name
次回の収益日
2026-08-06
Name
最新のSEC提出書
Name
VSTM's Discussions on Twitter

Compare VSTM vs VRTX, REGN, ARGX, ALNY, RVMD

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
VSTM icon
VSTM
Verastem Inc
4.12 362.04M 30.91M -209.47M -147.13M -3.3279
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
451.63 114.63B 12.34B 4.34B 3.71B 16.87
REGN icon
REGN
Regeneron Pharmaceuticals Inc
609.94 63.95B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
877.72 54.58B 4.16B 1.29B 734.26M 19.58
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
278.09 37.13B 4.29B 577.22M 641.34M 4.2086
RVMD icon
RVMD
Revolution Medicines Inc
162.99 34.65B 742.00K -1.37B -1.07B -7.0731

Verastem Inc Stock (VSTM) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-03-12 再開されました BTIG Research Buy
2026-02-04 開始されました H.C. Wainwright Buy
2025-10-16 再開されました Cantor Fitzgerald Overweight
2025-04-10 開始されました Jefferies Buy
2025-03-24 繰り返されました H.C. Wainwright Buy
2024-12-31 繰り返されました BTIG Research Buy
2024-09-30 開始されました Guggenheim Buy
2023-11-21 再開されました BTIG Research Buy
2023-09-27 開始されました B. Riley Securities Buy
2023-06-15 アップグレード Mizuho Neutral → Buy
2022-09-07 再開されました Alliance Global Partners Buy
2022-04-29 再開されました Cantor Fitzgerald Overweight
2022-04-14 開始されました RBC Capital Mkts Outperform
2022-03-09 開始されました Truist Buy
2021-07-01 開始されました Alliance Global Partners Buy
2021-05-24 アップグレード BTIG Research Neutral → Buy
2019-06-20 ダウングレード BTIG Research Buy → Neutral
2019-05-10 ダウングレード Raymond James Outperform → Mkt Perform
2018-07-13 開始されました BTIG Research Buy
2018-05-02 開始されました Seaport Global Securities Buy
2018-03-08 開始されました B. Riley FBR, Inc. Buy
2017-09-07 繰り返されました H.C. Wainwright Buy
2017-04-13 開始されました Oppenheimer Outperform
2017-03-24 繰り返されました H.C. Wainwright Buy
2015-09-29 ダウングレード Cantor Fitzgerald Buy → Hold
2015-09-29 ダウングレード JMP Securities Mkt Outperform → Mkt Perform
2015-09-29 ダウングレード Jefferies Buy → Hold
2015-09-29 ダウングレード Raymond James Strong Buy → Outperform
2015-09-28 ダウングレード Mizuho Buy → Neutral
2015-09-28 ダウングレード ROTH Capital Buy → Neutral
2015-09-09 開始されました Raymond James Strong Buy
2015-05-12 繰り返されました UBS Buy
2015-04-08 開始されました H.C. Wainwright Buy
2015-01-23 繰り返されました ROTH Capital Buy
2014-07-08 再開されました Oppenheimer Perform
2014-02-11 開始されました Mizuho Buy
すべてを表示

Verastem Inc (VSTM) 最新ニュース

pulisher
Jun 18, 2026

Verastem And The Biotech Side Of Penny Stocks - Kalkine Media

Jun 18, 2026
pulisher
Jun 18, 2026

Verastem stock holds Outperform at Mizuho on pancreatic trial data - Investing.com

Jun 18, 2026
pulisher
Jun 18, 2026

Verastem Inc (VSTM) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Jun 18, 2026
pulisher
Jun 17, 2026

Verastem Inc (VSTM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Jun 17, 2026
pulisher
Jun 17, 2026

Verastem Inc (VSTM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Jun 17, 2026
pulisher
Jun 17, 2026

Verastem Inc (VSTM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Jun 17, 2026
pulisher
Jun 17, 2026

Verastem (VSTM) Reveals Promising Results in Pancreatic Cancer S - GuruFocus

Jun 17, 2026
pulisher
Jun 17, 2026

Why Did Verastem Stock Jump After-Hours Despite An Earnings Miss? - Stocktwits

Jun 17, 2026
pulisher
Jun 17, 2026

Verastem: 'Buy' Positive RAMP-205 Data And Extensive VS-7375 Registration Program (VSTM) - Seeking Alpha

Jun 17, 2026
pulisher
Jun 17, 2026

Verastem Stock Jumps As Data Shows Strong Survival Trends In Pancreatic Cancer - Benzinga

Jun 17, 2026
pulisher
Jun 17, 2026

Verastem Oncology reports positive RAMP 205 data in front-line pancreatic cancer - grafa.com

Jun 17, 2026
pulisher
Jun 17, 2026

H.C. Wainwright Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $18 - Moomoo

Jun 17, 2026
pulisher
Jun 17, 2026

Verastem (Nasdaq: VSTM) reports RAMP 205 pancreatic data and starts KRAS G12D trial - Stock Titan

Jun 17, 2026
pulisher
Jun 17, 2026

Pancreatic cancer trial shows 86% six-month survival on Verastem drug combo - Stock Titan

Jun 17, 2026
pulisher
Jun 17, 2026

Verastem Inc (VSTM) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Jun 17, 2026
pulisher
Jun 17, 2026

Verastem (VSTM) Begins Patient Dosing in Crucial Cancer Trial - GuruFocus

Jun 17, 2026
pulisher
Jun 17, 2026

Verastem Inc (VSTM) Institutional Confidence - TradingKey

Jun 17, 2026
pulisher
Jun 17, 2026

Verastem Inc (VSTM) Valuation: PE, PB & Fair Value Analysis - TradingKey

Jun 17, 2026
pulisher
Jun 17, 2026

Verastem Inc (VSTM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Jun 17, 2026
pulisher
Jun 16, 2026

Verastem doses first Patient in TARGET-D 201 Phase 2 trial of VS-7375 - TipRanks

Jun 16, 2026
pulisher
Jun 16, 2026

Verastem, Inc. initiates first dosing in Phase 2 trial for KRAS G12D pancreatic cancer therapy - Traders Union

Jun 16, 2026
pulisher
Jun 16, 2026

Verastem Oncology announced that its oral inhibitor VS-7375, targeting Kras G12d-mutated metastatic pancreatic cancer, has completed dosing for the first patient in the Target-D 201 phase II registration-directed study. - Bitget

Jun 16, 2026
pulisher
Jun 16, 2026

Verastem doses first patient in pancreatic cancer trial By Investing.com - Investing.com Nigeria

Jun 16, 2026
pulisher
Jun 16, 2026

Verastem Oncology Doses First Patient in TARGET-D 201 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Pancreatic Cancer - Business Wire

Jun 16, 2026
pulisher
Jun 16, 2026

First patient receives KRAS G12D pill for metastatic pancreatic cancer - Stock Titan

Jun 16, 2026
pulisher
Jun 15, 2026

Verastem, Inc. plans conference to unveil progress on KRAS G12D trial - Traders Union

Jun 15, 2026
pulisher
Jun 15, 2026

Verastem Oncology to Host Investor Conference Call and Report Updated Data and Progress Across VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor TARGET-D Clinical Program - Business Wire

Jun 15, 2026
pulisher
Jun 10, 2026

Verastem, Inc. Stock Plummets to New 52-Week Low of $3.56 - MarketsMojo

Jun 10, 2026
pulisher
Jun 10, 2026

Analysts Offer Insights on Healthcare Companies: Verastem (VSTM), Jazz Pharmaceuticals (JAZZ) and Humana (HUM) - The Globe and Mail

Jun 10, 2026
pulisher
Jun 08, 2026

VSTM Technical Analysis & Stock Price Forecast - Intellectia AI

Jun 08, 2026
pulisher
Jun 04, 2026

Verastem’s VS-7375 receives FDA fast track status for lung cancer - Investing.com UK

Jun 04, 2026
pulisher
Jun 04, 2026

Verastem announces FDA Fast Track designation for VS-7375 - TipRanks

Jun 04, 2026
pulisher
Jun 04, 2026

Verastem Inc. (VSTM) Q1 2026 Earnings: Narrower-Than-Expected Loss Amid Ongoing Clinical ProgressEPS Surprise History - newsline.com

Jun 04, 2026
pulisher
Jun 04, 2026

Verastem, Inc. receives U.S. FDA fast track for KRAS G12D inhibitor in NSCLC treatment - Traders Union

Jun 04, 2026
pulisher
Jun 04, 2026

Verastem (VSTM) Surges 11% Following FDA Fast Track Designation - GuruFocus

Jun 04, 2026
pulisher
Jun 03, 2026

Verastem’s VS-7375 receives FDA fast track status for lung cancer By Investing.com - Investing.com South Africa

Jun 03, 2026
pulisher
Jun 03, 2026

Verastem (VSTM) Receives Fast Track Designation for Cancer Treat - GuruFocus

Jun 03, 2026
pulisher
Jun 03, 2026

Verastem stock rises on FDA fast track for lung cancer drug - Investing.com Canada

Jun 03, 2026
pulisher
Jun 03, 2026

Verastem Initiates Phase 2 Target-D 202 Trial For Advanced NSCLC - TradingView

Jun 03, 2026
pulisher
Jun 03, 2026

Verastem Oncology Announces U.S. FDA Fast Track Designation for VS-7375, an Oral and Potential Best-in-Class Investigational KRAS G12D (ON/OFF) Inhibitor for the Treatment of KRAS G12D-Mutated Locally Advanced or Metastatic Non-Small Cell Lung - Business Wire

Jun 03, 2026
pulisher
Jun 01, 2026

Verastem Inc stock (US92335V1008): Nasdaq-listed oncology player steadies around late-May levels - AD HOC NEWS

Jun 01, 2026
pulisher
May 29, 2026

VSTM Stock Price, Quote & Chart | VERASTEM INC (NASDAQ:VSTM) - ChartMill

May 29, 2026
pulisher
May 28, 2026

Mizuho Securities Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $14 - Moomoo

May 28, 2026
pulisher
May 27, 2026

Verastem (VSTM) Declines 2.5% as Biotech Sector Headwinds PersistPullback Trade - thelegaladvocate.com

May 27, 2026
pulisher
May 27, 2026

Verastem (NASDAQ: VSTM) director receives 108,000 restricted stock units - Stock Titan

May 27, 2026
pulisher
May 27, 2026

New Verastem (NASDAQ: VSTM) director files initial Form 3 ownership - Stock Titan

May 27, 2026
pulisher
May 27, 2026

[144] Verastem, Inc. SEC Filing - Stock Titan

May 27, 2026
pulisher
May 27, 2026

Biopharma Verastem Oncology joins Jefferies healthcare fireside chat June 3 - Stock Titan

May 27, 2026
pulisher
May 27, 2026

Verastem Oncology to Present at Jefferies Healthcare Conference - marketscreener.com

May 27, 2026
pulisher
May 27, 2026

Verastem: Robert Gagnon Stepped Down From Board Following End of Term on May 21 >VSTM - Moomoo

May 27, 2026
pulisher
May 26, 2026

Director at Verastem (VSTM) receives 36,000 RSUs as equity award - Stock Titan

May 26, 2026

Verastem Inc (VSTM) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$31.43
price up icon 0.74%
$90.89
price down icon 1.44%
$52.96
price down icon 1.38%
$63.96
price up icon 3.50%
ONC ONC
$270.15
price up icon 2.84%
$162.99
price up icon 3.31%
大文字化:     |  ボリューム (24 時間):